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INTRODUCTION 
Hypertension is one of the frontrunner causes of death and 
morbidity amongstAdults from all over the world. Hypertension perse is a 
major contributing risk factor for cerebral,coronary  and peripheral 
vascular disease. Essential hypertension accounts for about 90% of cases 
of hypertension.  
 Hypertension is an emerging health problem in India. When 
majority of people come to know that they have hypertension they have 
already advanced into a stage with target organ damage – a fatal stroke or 
myocardial infarction or irreversible renal failure. Unfortunately even in 
developed countries like United States, fifty million people are found to 
have hypertension.  
Hypertension and hyperuricemia were found to be associated when 
a family with an unfortunate pedigree attended Hammer Smith hospital in 
the United States in 1957. The father and six of the seven progeny had 
hyperuricemia, while the mother and all of the progeny had 
hypertension1.  
This incident incited interest in finding the correlation between 
serum uric acid levels and hypertension.   
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Reports suggesting an important association between increased 
levels of serum uric acid and elevated risk of coronary heart disease have 
surfaced repeatedly and is commonly seen in cases with essential 
hypertension, including untreated hypertension, and diabetes mellitus 
type 2, which are also independently associated with coronary artery 
disease.   
It is yet to be ascertained if the elevated serum uric acid levels 
increase the risk of hypertension and diabetes mellitus type 2 as an 
independent factor irrespective of acknowledged risk factors including 
age, obesity, alcohol consumption , and physical activity2.  
The close correlation between hyperuricemia and hypertension has 
been recognised for a long period. However  it is an unsolved doubt if the 
correlation of  hyperuricemia and hypertension is purely because of 
underlying renal and metabolic defects. Decreased blood flow to the 
kidneysand reduced tubular secretion of uric acid are frontrunners as the 
cause of  hyperuricemia in hypertension.  
 Here an attempt has been made to study the prevalence of elevated 
uric acid levels in essential hypertension and the correlation between 
elevated uric acid levels and hypertensive target organ damage.  
 
AIMS AND OBJECTIVES 
 
 
 
 
 
3 
 
 
AIMS AND OBJECTIVES 
1. To study the level of uric acid in patients with essential 
hypertension.  
 
2. To study whether any association exists between ages, sex, BMI, 
smoking, diabetes and target organ damage and the elevated uric 
acid. 
 
  
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
HYPERTENSION 
 Hypertension accounts for 1 in 8 deaths and therefore is the third 
most contributing cause of mortality in the world. Close to 1 billion 
people are afflicted withhypertension all over the world3. The prevalence 
of  hypertension among  people  increases proportionately with age. More 
than 50% of individuals aged 60 to 70 and about 75% of  those  aged 
more than 70 years are invariably affected. 
The Recent Framingham Heart Study has inferred that the lifetime 
risk in developing HTN is said to be 85 to 90% for males and females 
who are normotensive at 55-65 years of age and have survived to the age 
of 75-85 years4. Studies have shown that hypertension is an independent 
risk factor for CVD as diabetes mellitus is. The relationship between 
hypertension and cvd is independent, consistent and contiguous. All age 
groups ranging from 40 to 89 years old are at an increased risk. For every  
20 mm Hg increment in systolic or10mm diastolic both ischemic heart 
disease and stroke5 showed doubling of mortality. There is alsoincreased 
Evidencesuggesting greater importance of Systolic BP as a major risk 
factor for CVD. Systolic BP continues to rise throughout life, whereas 
DBP rises until approximately 50 years age, tends to plateau  over the 
next decade, and mostly  remains the same or may level down later in 
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life. Clinical trials have shown that adequate treatment and target  control 
of isolated systolic hypertension also brings down overall mortality, 
Cardiovascular  mortality, CVA and Heart failure events6, 7  
Definition:  
The best adapted definition of hypertension is “the level of BP at 
which the benefits (without the risks and costs) of action exceed the risks 
and costs (without the benefits) of inaction”8. 
Classification of Hypertension:   
Based on the 7th report of the Joint National Committee on 
prevention, detection, evaluation and treatment of high blood pressure 
(JNC 7 report) Blood pressure is classified  into the following stages- 
 
As a modification with the classification given in the JNC VI 
report, an additional category designated as  prehypertension has been 
added and stages 2 and 3 have been combined as a single stage 29.Patients 
with prehypertension are at increased risk for progression to 
 hypertension; those in the 130/80 to 140
the risk for the development of  hypertension as those with lower to 
normal  values10. 
Classification of Hypertension:
Patients with arterial hypertension and no explainable cause are 
defined as having 
Secondary form of hypertension 
structural organ or gene defect 
 
 
6 
/90mm Hg BP range have double 
 
primary, essential or idiopathic hypertension. 
 is seen in Individuals in whom a specific 
causative of  hyper 
 
7 
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. Medications e.g. Glucocorticoids, cyclosporine, NSAIDS 
V. Unknown etiology 
A. Essential hypertension (>90% of all hypertension) 
B. Toxemia of pregnancy 
C. Acute intermittent porphyria 
Genetic Considerations 
Multiple genes play a major role n essential hypertension, making 
it a polygenic disorder, with each gene having relevant effects12. 
 
Natural course of Untreated Hypertension:  
Both the rising SBP and falling DBP levels logically are linked 
with an accelerated  risk of  atherosclerotic  diseases. One of the best 
prognostic indicators in hypertension is the resultant widening pulse  
  
9 
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pressure. However, an analysis of data from one million adults in 61 
prospective studies discovered  that for predicting mortality from both 
stroke and  coronary disease, SBP is slightly more informative than DBP 
and that the  pulse pressure is much less informative13. 
Symptomatology and Clinical Signs: 
 Patients with uncomplicated hypertension are usually asymptomatc 
and are unaware of cardiac and vascular complications even as long as  
5 to 20 years. Normotensive population also have symptoms usually 
associated with hypertension such as headache, fainting, tinnitus and 
giddiness. Upon diagnosis of hypertension, patients may also have 
symptoms of hypertension that are probably psychogenic due to anxiety 
over the insidious disease. 
Based on symptomatology, patients are graded into 3 categories. 
1. Underlying contributing disease in secondary hypertension 
2. The elevated pressure per se 
3. Cardiovascular disease due to hypertension 
Headache  although it is commonly associated with hypertension is 
only seen n severe hypertension, usually localized to the occipital region 
worsening during the morning hours while awakening and subsides later 
on. Complaints related to hypertension are impotence, palpitation, 
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dizziness and easy fatigability. Cardio vascular complaints related to 
hypertension are  
1. Blurring vision due to papilledema 
2. Epistaxis, haematuria 
3.  Weakness or fainting due to transient ischemic attack 
4. Dyspnoea and angina due to hypertension  heart failure  
5. Abdomen pain related to aortic dissection or burst aneurysm 
6. Primary hyperaldosteronsm causing polydipsia, polyuria, 
hypokalaemia induced muscle weakness 
7. Cushing’s  syndrome causing weight gain 
8. Pheochromocytoma presenting with fleeting episodes of 
palpitation, headaches, excessive sweating and postural 
hypotension15. 
Hypertension associated with other ailments: 
1.Obesity 
Hypertension is more prevalent among obese persons and gives in 
to their elevated risk of IHD especially if it is abdominal/visceral in 
location as a part of the metabolic syndrome. In the Framingham Study 
the incidence of hypertension was increased 46 % in men and 75 % in 
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female who are overweight regarded as a body mass index of 25.0 to 29.9 
compared to normal weight persons16. 
2. Physical Activity:  
Hypertensives can lower their BP by means of regular aerobic 
exercise and physical fitness plays an important role in prevention of 
hypertension. Above said  relationship may involve a restoration of age 
related decline in endothelium dependent vasodilation17. 
4. Alcohol Intake:  
Alcohol in large amounts (more than 2 portions daily and even 
more so during binge drinking), alcohol increases BP and arterial 
stiffness. Alcohol has pressor effect on hear and blood vessels causing 
tachycardia and increased cardiac output owing mainly to increased 
sympathetic nerve activity. Alcohol increases permeability of cell 
membrane and indirectly by inhibition of sodium transport allows more 
calcium to enter. 
4. Smoking: 
Cigarette smoking raise blood pressure, because  adrenergic nerve 
endings release  nor-epinephrine induced by nicotine.  
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5.Hyperuricemia:  
Hyperuricemia is present in 25 – 50 % of persons with untreated 
essential hypertension, over 5 times the frequency seen in normotensive 
persons. Hyperuricemia presumably a reflection of nephrosclerosis18   is 
due to decreased renal blood flow. 
6. Sleep Apnea: 
Sleep and snoring are frequently associated with hypertension, 
which may in turn be stimulated by increased sympathetic activity and 
hypoxemia inducedendothelinrelease  during apnea. Relief of sleep apnea 
may alleviate hypertension19. 
7. Hematological Findings:  
Higher haematocrits are found in hypertensive persons and 
associated with abnormal left ventricular filling on echocardiography20. 
8. Hypercholesterolemia: 
Hypercholesterolemia frequently coexists with hypertension at 
least in part because it impairs endothelium dependent vasodilation. Lipid 
lowering therapy restores the bioavailability of nitric oxide, reduces 
arterial stiffness and lowers BP21. 
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MECHANISM OF HYPERTENSION: 
Primary hypertension is preferred to essential hypertension when 
there s no known cause for hypertension after extensive evaluation. 
Defects  may be present in one or more of the multiple factors that affect 
the two forces namely persistent hypertension can develop only in 
response to an increase in peripheral vascular resistance or  cardiac output 
as shown in the figure below. The interplay of various anomalies in 
factors affecting peripheral resistance and cardiac output may precipitate 
the disease, and these abnormalities may differ in degree and type in 
various patients. Figure 1- Some of the factors involved in the 
regulation22of blood pressure . 
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Complications of Hypertension:  
Hypertension if left untreated, more than 45 % of hypertensive 
patients die of Congestive Failure or Coronary Heart Disease, about 34 % 
of Stroke, and 15 to 18% of renal failure. Patients with malignant 
accelerating hypertension die more due to acute renal failure, and also 
those who are diabetic once other evidence of nephropathy and 
proteinuria develops. 
Effect of Hypertension on the Eye:  
Vascular changes in the fundus reflect both arteriosclerotic 
retinopathy and hypertensive retinopathy. The hypertensive retinal 
changes are graded by the Keith – Wegner – Baker classification as23  
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Effects on the heart:  
Abnormalities in Left Ventricular Function- the earliest functional 
changes in hypertension are in left ventricular diastolic dysfunction, with 
lower E/A ratio and longer isovolemic relaxation time24. 
17 
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Left Ventricular Hypertrophy-  
Hypertrophy occurs as a response to the increased afterload due to 
elevated systemic vascular resistance. Variety of dysfunctions accompany 
LVH, including lower coronary vasodilating capacity, abnormal left 
ventricular diastolic filling pattern and depressed left ventricular wall 
mechanics 25 
 
Figure 2 : Complications of systolic and diastolic dysfunction related 
to hypertension26 
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Congestive Heart Failure-  
The various scenarios of systolic and diastolic function seen in 
relation to LVH can progress into congestive heart failure. A 20mm Hg 
increment in systolic blood pressure conferred a 54% increased risk of 
CHF in the Framingham cohort. When haemodynamically challenged by 
stress, there is inability to increase their end diastolic volume in persons 
with hypertension , because of decreased left ventricular compliance and 
relaxation. It leads to a cascade, in which left atrial pressure increases, 
left ventricular end diastolic blood pressure rises,  and pulmonary edema 
ensues27. 
Coronary artery Disease-  
Hypertension is a dreaded risk factor for myocardial infarction and 
ischemia. Acute rise in blood pressure may follow the onset of ischaemic 
pain; the blood pressure often falls immediately after the infarct if 
systolic function is impaired. Once an MI occurs, both the pre-existing 
and the subsequent blood pressure affect the prognosis28.silent MI is 
increasingly seen in hypertensives and also they are associated with 
higher mortality. 
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Effect on the Kidneys  
 Increased retention of water and salt by the kidneys is the likely 
triggering mechanism here. Dysfunction of kidneys not normally 
recognised is responsible for most cases of hypertension. Intraglomerular 
hypertension in the form of microalbuminuria is seen in many  
hypertension patients suggesting functional damage and structural 
derangements. Microalbuminuria in hypertension patients has been 
associated with left ventricular hypertrophy and carotid artery thickness. 
Progressively hypertension leads to nephrosclerosis and furthermore 
leading to elevated serum creatinine and ultimately renal failure. 
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Effect on the Central Nervous System:  
systolic hypertension is a major contributing  risk factor for both 
intracerebral  hemorrhage and ischaemic stroke. Caution is advised in 
lowering blood pressure during this crucial periodas Blood pressure 
usually goes up further during the acute phase  of a stroke. 
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Hyperuricemia  and Hypertension: 
Raised concentrations of serum uric acid in the blood are 
commonly seen in essential hypertension. Even though the treatment of 
hypertension is frequently associated with gout and Hyperuricemia, 
Hyperuricemia relatively frequently precedes treatment and even so 
before diagnosis. The hyperuricemia found  in untreated hypertension 
may reflect early hypertensive nephrosclerosis  due to the decrease in 
renal blood flow. Hyperuricemia -associated morbidity and mortality is 
usually confounded by the drugs like thiazide diuretics which confound 
the link.  It is essential to know about The renal handling of uric acid so 
that it may provide a damning clue as to why serum uric acid is very 
closely linked to hypertension associated morbidity. As arterial blood 
pressure rises serum uric acid increases and is associated with a reduction 
in renal vasculature. 
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Figure 3 - Interaction between renal pathophysiology of 
Hypertension and uric acid biochemistry 
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CHEMISTRY OF URIC ACID AND ITS OXIDATION 
PRODUCTS:  
The chemical structure of uric acid as shown by Fischer as 2, 6, 
and 8-Trihydroxypurine 
 
Uric acid is the most oxidizable member of the purines. Further 
oxidation of uric acid in alkaline solution causes damage  of purine ring 
with removal of C 6 as carbon dioxide and production of Allantoin along 
with other degradation products.  
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Uric Acid Production:  
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1. PRPP synthetase. 
2. Hypoxanthine guanine phosphoribosyltransferase.  
3. Adenine phosphoribosyltransferase. 
4.Adenosinedeaminase. 
5.Xanthine oxidase 
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While the purine pathway is regulated in an extremely complicated 
manner, the intracellular concentration of 5-phospho-ribosyl-I-
pyrophosphate (PRPP) appears to be a major determinant of the rate of 
synthesis of uric acid in humans. Generally when the concentration of 
PRPP within the cell is high, uric acid synthesis is elevated, when the 
concentration of PRPP is reduced the synthesis of uric acid is also 
reduced33.  
Overproduction of uric acid in a minority of adult gouty subjects 
occurs as a primary or a secondary manifestation of an inborn error in 
metabolism. Hyperuricemia and gout occur as a primary manifestation of 
partial hypoxanthine – guanine - phosphor ribosyltransferase deficiency 
and of   PRPP synthetase super activity. In the Lesch-Nyhan syndrome 
the complete deficiency of hypoxanthine guanine phosphoribosyl 
transferase results in secondary hyperuricemia.. 
In some increased excretion of uric acid is related, as it is in 
primary gout, to an accelerated rate of purine biosynthesis de novo. 
Patients with glucose-6-phosphatase deficiency (Type I Glycogen storage 
disease) uniformly exhibit an increased production of uric acid as well as 
an accelerated rate of purine biosynthesis de novo. Overproduction of 
uric acid in patients with this enzyme defect is multifactorial. An 
accelerated rate of purine biosynthesis de novo may be due in part to 
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accelerated synthesis of  PRPP. Additionally, accelerated degradation of 
purine nucleotides, contributes to an increased rate of uric acid excretion. 
Both of these mechanisms are due to the deficiency of glucose as an 
energy source, and the production of uric acid can be decreased by them 
sustained correction of hypoglycemia in this disorder. In the majority of 
patients with secondary hyperuricemia due to an overproduction of uric 
acid, the predominant abnormality appears to be an increased turnover of 
nucleic acids.  
A number of  diseases, including the myeloproliferative and 
lymphoproliferative disorders, multiple myeloma, secondary 
polycythemia, pernicious anemia, certain hemoglobinopathies, 
thalassemia, other hemolytic anemia’s, infectious mononucleosis and 
some carcinomas  may be associated with increased marrow activity or 
increased turnover of cells in the marrow or at other sites and an 
associated increased turnover of nucleic acids. The increased turnover in 
nucleic acids leads in turn to hyperuricemia, hyper uricaciduria and a 
compensatory rise in the rate of purines biosynthesis de novo32. 
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Uric Acid Excretion                                                                                                          
 
FIG.-6 Diagrammatic Representation of Normal Renal  
Handling of UricAcid. 
The numbers tell us the percentage of the filtered urine in transport. 
The excretion of uric acid is dependent on glomerular filtration, tubular 
reabsorption and tubular secretion. Uric acid appears to be completely 
filtered at the glomerulus and reabsorbed in the proximal tubule (i.e., 
presecretoryreabsorption). Uric acid secretion then occurs in a subsequent 
segment of the proximal tubule, and partial reabsorption takes place at a 
second reabsorption site in the distal part of the proximal convoluted 
tubule (i.e., post secretory reabsorption). 
While some uric acid reabsorption may also occur in the ascending 
limb of Henle’s loop and in collecting duct, these latter two sites are 
33 
 
thought to be quantitatively less important. Finally about 6 – 12% of the 
filtered urate load is excreted in urine – Fig. 6Altered renal excretion of 
uric acid exhibiting hyperuricemia could be due to 1. Reduced filtration 
of uric acid.2.Enhanced reabsorption. 3. Decreased secretion. No 
unequivocal data establish any one of these mechanisms as the basic 
defect, and it is likely that all three are operative within the hyperuricemic 
population.  
Patients with renal disease usually have a reduction in glomerular 
filtration rate leading to decreased filtered load of uric acid and thus 
hyperuricemia. The Tubular reabsorption of uric acid is active process 
that is closely related to sodium reabsorption. Therefore states of volume 
contraction (with enhanced sodium reabsorption) are accompanied by 
increased urate reabsorption and decreased urate clearance. Diuretic 
induced volume depletion leads to enhanced tubular reabsorption of uric 
acid as well as decreased uric acid filtration.  
In some situations hyperuricemia has been attributed to competitive 
inhibition of uric acid secretion by excess organic acids thought to be 
secreted by the same renal tubular mechanism responsible for uric acid 
secretion. Examples include starvation (ketosis and free fatty acids), 
diabetic ketoacidosis, alcoholic ketosis, lactic acidosis of any cause and 
maple syrup urine disease. 
34 
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Classification of Hyperuricemia by Pathophysiology 
1) Urate overproduction- Primary idiopathic 
b) HPRT deficiency 
c) PRPP synthetaseoveractivity 
d) Hemolytic process 
e) Lmphoproliferative diseases 
f) Myeloproliferative diseases 
g) Polycythemia vera 
h) Psoriasis 
i) Paget’s disease 
j) Glycogenosis III, V, and VII 
k) Rhabdomyolysis 
l) Exercise 
m) Alcohol 
n) Obesity 
o) Purine-rich diet 
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2) Reduced Uric acid Excretion 
a) Primary - idiopathic 
b) Renal insufficiency 
c) Polycystic kidney disease 
d) Diabetic insipidus 
e) Hypertension 
f) Acidosis 
i) Lactic acidosis 
ii) Diabetic ketoacidosis 
g) Starvation ketosis 
h) Berylliosis 
i) Sarcoidosis 
j) Lead intoxication 
k) Hyperparathyroidism 
l) Hypothyroidism 
m) Toxemia of pregnancy 
n) Bartter’s syndrome 
37 
 
o) Down syndrome 
p) Drug ingestion 
i) Salicylates (>2g/d) 
ii) Diuretics 
iii) Alcohol 
iv) Levodopa 
v) Ethambutol 
vi) Pyrazinamide 
vii) Nicotinic acid 
viii) Cyclosporine 
 
3) Added Mechanism 
a) Fructose-1- phosphate aldolase deficiency 
b) Glucose 6 phosphatase deficiency 
c) Shock 
d) Alcohol 
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 In the following Hospital based study for the CORRELATION OF 
SERUM URIC ACID LEVELS IN ESSENTIAL HYPERTENSION 250 
patients who attended the out-patient and in-patient at the department of 
Medicine were evaluated for Serum Uric Acid levels of which 150 were 
cases and 100 Were controls.   
 Period of study :  April 2016  to September 2016 
Study design   :  Cross sectional study  
Study conducted :  Madras medical college hospital, Chennai.  
Sample size    :  250 subjects. 150 were cases and 100 were  
    control.  
Patient selection :  cases 
 
INCLUSION CRITERIA  
1. Patients with essential hypertension  
2. Both sex were included  
3. Patients above age 25 were included.  
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EXCLUSION CRITERIA  
1. Patients below 25 years were excluded Patients with renal failure   
2. Patients with secondary hypertension.  
3. Patients whom consumes alcohol regularly 
4. Patients on chemotherapy and antimetabolite  
5. Clinical Findings of gout or extra- articular manifestations of   
     Hyperuricemia. 
6. H/o drugs known to cause hyperuricemia, e.g. thiazide diuretics  
7. Pregnancy  
 
CONTROLS:  
Controls were patients without hypertension or any other condition 
known to cause hyperuricemia and were matched for age and sex with 
that of the cases.  
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Data collection and measurements:  
The clinical examination consisted of a detailed medical history, 
complete physicalexamination,including blood pressure measurement, 
anthropometric measurements, measurement of fasting serum uric acid 
levels and other parameters like Blood haemogram, Renal function tests 
(blood urea, serum creatinine),  
Electrocardiogram were recorded in all patients.  
The patients were asked to fast for 12 hours and to avoid smoking 
and heavy physical exercise for more than 2 hours before the 
examinations.  
After a 5min rest in a quiet room, systolic and diastolic blood 
pressures were measured in the sitting position twice at an interval of a 
few minutes on the right arm with a standard mercury 
sphygmomanometer on three separate occasions.  
Anthropometric measurements included height and body weight, 
which were measured while the subject was wearing light clothing 
without shoes. The body mass index was calculated as the weight in 
kilograms divided by the height in m2.  
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LABARATORY DATA 
Blood urea: Estimation done manually by using Diacetylmonoxime 
(DAM) technique.  
Serum creatinine: Estimation done based on JAFFE’S reaction. 
ESTIMATION OF SERUM URIC ACID(METHOD OF CARAWAY)  
Principle: Uric acid is oxidised to allantoin by phosphotungsticacid.This 
acid is further reduced to tungsten blue in alkaline sodium carbonate 
medium. Thecolour of the solution is proportional to the concentration of 
uric acid present in the sample. It is measured in the photoelectric 
colorimeter at 620 nm(red filter)  
REAGENTS:  
a.10% Sodium Tungstate. 
b.2/3 N sulphuric acid  
c.Phosphotungstic acid.  
d.14% sodium carbonate. 
e.Standard uric acid solution(10 mgs%)  
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DEFINITIONS USED IN THE PRESENT STUDY  
1. ESSENTIAL HYPERTENSION: 
According to the JNC VII report, hypertension is defined as 
systolic pressure of 140 mm hg and above and or diastolic blood pressure 
of 90 and above.  
2. HYPERURICEMIA: 
It is defined as serum uric acid levels >7mgs/dl in males and 
>6mgs /dl in females.  
3. BODY MASS INDEX:   
Bmi<18.5 are underweight, 18,5-24.9 are normal,25-29.9 are 
overweight,> 30 obese  
4. DIABETES MELLITUS:  
Fasting blood sugar=126 mg/dl  
Two hour blood sugar=200mg/dl  
Already known case of diabetic on treatment  
Symptoms of diabetes plus random blood sugar=200mg/dl             
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5. LEFT VENTRICULAR HYPERTROPHY:  
Based on electrocardiographic findings satisfying either 
SOKOLON-LYON criteria or CORNELL voltye criteria  
HYPERTENSIVE RETIN0PATHY   
Based on KEITH-WAGNER-BARKER grading  
Grade 1   -   attenuation of arteries. 
Grade 2   -   arterio-venous nipping. 
Grade 3   -   with haemorrhage and exudates. 
Grade 4   -   with papilledema  
  
OBSERVATIONS AND RESULTS  
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OBSERVATION AND RESULTS 
 This study group included total number of 250 subjects, among 
these 150 was cases and 100 were controls. 
ANALYSIS OF CASES AND CONTROL ACCORDING TO AGE 
Tab.1DISTRIBUTION OF AGE AMONG CASES AND 
CONTROLS 
 GROUP N Mean Std. Deviation 
Std. Error 
Mean 
P value 
AGE 
CONTROL 100 50.4200 10.80421 1.08042 0.068 
CASE 150 53.0133 11.04900 .90215  
 
The age of the study population ranged from 26 to 76 years. The 
mean and standard deviation of age for cases and controls were 53.013+ 
11.05 and 50.42+ 10.804 respectively. There was no significant 
difference in the age composition of those with and without hypertension 
in this study (p value- 0.068) hence elevated serum uric acid among cases 
and controls were independent of age. 
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SEX DISTRIBUTION IN THE STUDY POPULATION 
 
TAB.2 DISTRIBUTION OF STUDY POPULATION IN  
RELATION TO GENDER 
 
SEX 
Total 
 
MALE FEMALE P value 
GROUP 
CONTROL 
Count 56 44 100  
% 56.0% 44.0% 100.0% 0.054 
CASE 
Count 102 48 150  
% 68.0% 32.0% 100.0%  
Total 
Count 158 92 250  
% 63.2% 36.8% 100.0%  
 
 
Among the 150 cases studied, there were 102 male and 48 females. 
Among the 100 controls, 56 were male and 44 were female. 
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TAB.3 BMI DISTRIBUTION IN THE STUDY POPULATION 
 
 
BMI CLASS  
 
Total 
  
 
<25 
 
>=25 
 
Mean 
 
sd 
 
P value 
CONTRO
L 
Count 77 23 100  
 
22.98 
 
 
 
2.71 
0.098 
% 77.0% 23.0% 100.0% 
CASE 
Count 101 49 150 
 
23.01 
 
2.95 % 67.3% 32.7% 100.0% 
Total 
Count 178 72 250  
% 71.2% 28.8% 100.0%  
 
The mean and standard deviaton of BMI for cases and controls 
were 23.01+ 2.95And 22.98+ 2.71 respectively. The dfference in BODY 
MASS INDEX between cases and controls were statistically not 
significant (p – 0.098) 
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DISTRIBUTION OF SYSTOLIC AND DIASTOLIC BP AMONG 
STUDY GROUP 
 
 Count Mean 
Standard 
Deviation 
GROUP 
CONTROL SBP 100 116.10 7.19 
CASE SBP 150 159.68 15.50 
CONTROL DBP 100 78.20 6.05 
CASE DBP 150 100.23 8.79 
 
The mean and standard deviation of systolic and diastolic BP in 
case Were159.68+15.50 and 150+8.79 respectively. 
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DISTRIBUTION OF CASES AND CONTROLS IN 
RELATION TO RENAL PARAMETERS AND SUGAR   
TAB.5 Distribution of study population in relation to  
renal parameters 
 
 Count Mean Standard Deviation  
RBS 
Control 100 106.32 9.82  
 
0.247 Case 150 110.27 33.10 
B.UREA 
Control 100 29.30 2.96  
 
0.171 Case 150 29.53 5.82 
S.CREAT 
Control 100 .89 .18  
 
0.677 Case 150 .92 .22 
 
There was no statistical significance in distribution of cases and 
controls n relation to blood sugar, urea and creatinine. 
  
56 
 
ANALYSIS OF CASES RELATED TO TARGET ORGAN 
DAMAGE 
TAB.6 Distribution of cases in relation to TOD 
 Count % 
LVH 
NO 129 86.0% 
YES 21 14.0% 
CAD 
NO 106 70.7% 
YES 44 29.3% 
CCF 
NO 132 88.0% 
YES 18 12.0% 
CVATIA 
NO 131 87.3% 
YES 19 12.7% 
PAD 
NO 149 99.3% 
YES 1 0.7% 
RETINO 
NIL 87 58.0% 
Grade1 30 20.0% 
Grade 2 24 16.0% 
Grade 3 6 4.0% 
Grade 4 3 2.0% 
 
 Among 150 cases, LVH w
in 44 cases , CCF was  present in 18 cases, CVA/TIA w
cases and hypertensive retinopathy was seen in 63 cases.
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TAB .7 Distribution of serum uric acid among study population 
 
 
 
GROUP 
 
 
No 
 
 
Mean 
 
 
Std. Deviation 
 
 
 
Std. Error 
Mean 
 
SUA 
CONTROL 100 4.0020 .56604 .05660 P<0.001 
CASE 150 5.4400 1.22972 .10041  
 
          The mean and standard deviation of serum uric acid among cases 
were 5.44+1.23 while in control it was 4.002+0.57. this table clearly 
shows that serum uric acid level was significantly influenced by systemic 
hypertension. 
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DISTRIBUTION OF CASES AND CONTROLS IN 
RELATION TO HYPERURICEMIA 
TAB.8 Comparison of mean UA levels among  
cases and controls 
 
SUA  
Count % Mean Standard Deviation  
 
 
 
NORMAL <7 
 
 
 
GROUP 
 
 
CONTROL 
100 100.0% 4.00 .57 
P<0.001 
 
CASE 128 85.3% 5.10 .97 
 
 
 
ABNORMAL>7 
 
 
 
GROUP 
 
 
CONTROL 
0 0.0% 
  
 
CASE 22 14.7% 7.45 .32 
 
 22 cases had hyperuricemia while none of the controls 
hadhyperuricemia.This table clearly shows hyperuricemia was 
statistically significant in hypertensiveswhen compared to normotensives. 
Hyperuricemia was present in 14.67% of hypertensives 
  
 DISTRIBUTION OF URIC ACID LEVEL IN 
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SEX DISTRIBUTION OF SERUM URIC ACID IN STUDY 
POPULATION 
TAB.9 comparison of uric acid levels among the study groups 
 SEX No Mean Std. Deviation 
Std. Error 
Mean P VALUE 
CONTROL 
MALE 56 4.0607 0.64433 0.08610  
 
0.244 
FEMALE 44 3.9273 0.44322 0.06682 
CASE 
MALE 102 5.5059 1.26513 0.12527  
 
0.341 
FEMALE 48 5.3000 1.15113 0.16615 
 
The mean serum uric acid levels in hypertensive males and females 
were 5.5+1.27 and 5.3+1.15 respectively. P value is not statistically 
significant. 
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TAB.10 Relationship between BMI and URIC ACID 
LEVEL in cases and controls 
 
 
 
 
 
SEX 
 
 
No 
 
 
Mean 
 
 
Std. 
Deviation 
 
 
Std. Error 
Mean 
 
 
P VALUE 
CONTROL 
<25 77 4.0519 0.52431 0.05975 
 
 
 
0.107 >=25 23 3.8348 0.67394 0.14053 
CASE <25 101 5.5327 1.16526 0.11595  
 
 
 
0.186  >=25 49 5.2490 1.34538 0.19220 
 
This table shows BODY MASS INDEX was not statistically 
significant influencing the serum uric acid levels. In the study population, 
BMI < 24.9 was seen in 101 cases and the mean serum uric acid was 
5.53+1.17. BMI > 25 was seen in 49 cases and the mean serum uric acid 
was 5.25+1.35 respectively. 
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TAB.11.SERUM URIC ACID LEVEL IN HYPERTENSIVE 
SUBJECTS WITH AND WITHOUT DIABETES 
 
 DIABETES No Mean Std. Deviation 
Std. Error 
Mean P VALUE 
YES 31 4.5032 0.87692 0.15750 0.082 
NO 219 4.9160 1.27325 0.08604  
 
The mean serum uric acd level in hypertensives with and without 
diabetes was 4.5+0.88 and 4.9+1.27 respectively. The serum uric acid 
level in cases with and without target organ damage was not statistically 
significant (p value 0.082). 
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TAB.12 SERUM URIC ACID LEVELS IN RELATION TO 
SMOKERS IN STUDY POPULATION 
 
 SMOKING No Mean 
Std. 
Deviation 
Std. Error 
Mean 
P VALUE 
 
YES 73 4.8726 1.00406 0.11752 0.949 
NO 177 4.8616 1.32399 0.09952  
 
 This table showed smoking did not influence the serum uric acid 
levels significantly. The mean serum uric acid level of smokers in this 
study group was4.87+1.00 when compared to non smokers 4.86+1.32. 
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TAB.13 SERUM URIC ACID LEVEL IN RELATION TO 
ORGAN DAMAGE 
 
SUA  
Count Mean Standard Deviation  
LVH 
NO 229 4.69 1.10 
P<0.001 
YES 21 6.74 1.13 
CAD 
NO 206 4.62 1.11 
P<0.001 
YES 44 6.00 1.17 
CCF 
NO 232 4.80 1.21 
P<0.001 
YES 18 5.73 1.32 
CVATIA 
NO 231 4.79 1.18 
P<0.001 
YES 19 5.74 1.55 
RETINO 
YES 63 5.7968 1.31357 
P<0.001 
NIL 187 4.5508 1.03946 
 
 
 
DISCUSSION 
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DISCUSSION 
Elevated  SUA levels have been associated with an increased risk 
for cardiovascular disease. Enhanced platelet aggregation and 
inflammatory activation of the endothelium41  are The mechanisms by 
which SUA may directly affects cardiovascular. 
 In few studies, the association of SUA with cardiovascular disease 
was uncertain after multivariate adjustment as in the Framingham Heart 
Study (1985) and the ARIC study (1996), but in others the association 
remained certain and significant. 
 Because elevated serum uric acid is correlated with several risk 
factors including hypertension, renal dysfunction , insulin resistance 
,hyperlipidemia and hyperhomocystenemia, it is  a major debate whether 
SUA independently causes cardiovascular risks. 
Various other reports have also shown that increased Serum Uric 
Acid levels were seen in hypertensive patients. Kinsey (1961) in his study 
with 400 hypertensive patients reported a 46 % incidence of 
hyperuricemia in hypertensives42. Kolbe (1965) in his study of 46 
hypertensive patients found 26 to be having increased SUA levels  
(56%) 43. 
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A. Breckinridge (1966) demonstrated  273 of 460 patients on 
antihypertensives, (57%) had elevated Serum UA levels and 92 of the 323 
patients (28%) attending the hospital for the time had hyperuricemia1. A 
study by C. J. Bulpitt (1975) showed that 41 % female hypertensivesand  
47 % male hypertensives  had hyperuricemia44. 
Ramsay (1979) in his study of 73 men with untreated hypertension 
had 18 with raised serum uric acid levels (25%) 45. Meserli et al (1980) 
proved an incidence of 71 % raised Serum UA in their case population of 
38 established hypertensives. Meserli and Frolich et al demonstrated that 
the significant presence of hyperuricemia in hypertensives construes to  
underlying renal failure46. 
 There is sufficient evidence that uric acid is sensitive and earlier as 
a marker for renal failure than creatinine. Serum UA has a role in the 
generation of free radicals. Free radcals inhibit vasodialtion of 
endothelium. Thus antioxidant drugs show a BP lowering effect. 
Canon et al considered that an impairment of renal function will 
raise the SUA levels more commonly than an increased SUA will cause 
renal damage50. Hence it is unlikely that hypertension arises as a result of 
raised SUA levels, but the possibility that uric acid which plays a role in 
the production of oxidative stress and free radicals must mostly correlate 
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with elevated formation of free radicals. Hence the fact that raised SUA 
levels can lead to Hypertension cannot be entirely ruled out. 
 Among  the 150 cases of hypertension ,hyperuricemia was seen in 
29 cases, which is 19% of cases. Canon et al 1996 showed a prevalence 
of hyperuricemia in 25% of untreated hypertensive cases. 
 The Framingham study observed that the correlation of   blood 
pressure with uric acid was reduced in the case population as they 
increased in age (source: Feig and Johnson 2003). The Olivetti heart 
study (joss et al,1994) has shown an independent positive correlation 
between development of hypertension and serum uric acid. 
  The mean age for cases in this study is 52.74 years.This might 
explain the lower  prevalence  of  hyperuricemia  when compared  with  
Feig and  Johnson et al(2003). 
The mean serum uric acid level in male is 5.5+1.26  while in 
female it is 5.4+ 1.15 . This correlates with the study done by ketker et 
al(1979) in which they have shown that the serum UA level was more in 
males when related to females. 
 In this study of cases serum uric acid do not correlate with Body 
Mass Index. The average serum UA level in hypertensive with BMI <23 
and BMI =23  are 5.38 mg/dl and 5.4 mg/dl and the difference is not 
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satistically significant. Shobakaelker et al and healiey have proved in 
their  study that there was no significant correlation between obesity and 
serum uric acid level.  
The serum uric acid level is significantly higher in hypertensives 
when compared to normotensives. The average serum uric acid level in 
cases is 5.44mg/dl while in the control it is 3.96mg/dl.This is consistent 
with other studies ,which has shown  elevation of serum uric acid in 
hypertension. 
   In this study 87% of  hypertensives has serum uric acid level 
>4mg/dl,  while in controls 47% of subjects have serum uric acid level 
>4mg/dl.In a review article by hayden et al (2004) it was noted that 
elevation of serum uric acid level >4mg/dl isa RED FLAG sign in 
cardiovascular disease.  
 There is no significant correlation  between diabetes and serum uric 
acid level in this study.Smoking which is also a cardiovascular risk factor 
does not significantly influence serum uric acid level in the current study. 
 
  Serum uric acid levels are significantly and independently  related 
to increased risk of cardio-vascular mortlity(JAMA.2000;283:2404-
2410). In our study coronary arterial disease is seen in 44 hypertensive 
individuals. The mean serum uric acid level in cases with CAD is 
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6+1.17.There is significant difference noticed among the cases with and 
without CAD( P-VALUE <0.001). 
 In our study we found that there is definite relation in SUA levels 
between normotensive patients and hypertensive patients.  Hence the 
possibility of serum uric acid acting by the formation of free radicals and 
causing oxidative stress leading to renal dysfunction as the result of 
nephrosclerosis leading to higher levels of serum uric acid has to be 
considered, as various other studies have also show to have a positive 
relation in the SUA levels and hypertension. There are controversies with 
reference to elevated uric acid as an independent risk factor for 
cardiovascular disease, it is suggested to carry out similar prospective 
studies among newly detected hypertensive population and follow them 
to ascertain truth. 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
1. We decided that there can be a direct relation between hypertension 
and hyperuricemia based on the results of our study. 
2. Hyperuricemia is found in 15.5% of hypertensives while none of 
the normotensives had hyperuricemia. 
3. Serum uric acid level is significantly elevated in cases with 
coronary artery disease(p-value<0.001)  
4. Serum uric acid is significantly elevated in essential hypertension. 
5. There is no correlation between serum uric acid with age, sex, 
BMI, diabetes and smoking. 
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ANNEXURES 
 
  
LIST OF ABBREVIATIONS 
AAP 4  -  Amino antipyrine 
 
AmidoPRT  - Amido phosphoribosyl transferase 
AMP   - Adenylic acid 
ATP    - Adenosine triphosphate 
BL.UREA   - Blood urea 
BMI    - Body mass index 
BP    - Blood Pressure 
CCF    - Congestive cardiac failure 
CVA    - Cerbro vascular accident. 
CVD    - Cardio Vascular Disease 
DM    - Diabetes mellitus 
DBP    - Diastolic Blood Pressure 
GFR    - Glomerular Filtration rate 
GMP   - Guanylic acid 
HF    - Heart Failure 
HPRT   - Hypoxanthine phosphoribosyl transferase 
HTN    - Hypertension 
IHD    - Ischemic Heart Disease 
JNC    - Joint National Committee 
MI    - Myocardial infarct 
PRPP   - Phosphoribosyl pyrophosphate 
SBP    - Systolic blood pressure 
SR.CREAT  - Serum creatinine 
SUA    - Serum uric acid 
TIA    - Transient ischemic attack 
 
  
PROFORMA 
Name:         AGE:      SEX:     IP/OP NO:  
BMI:  
 
COMPLAINTS: 
 
PAST H/O:  
DIABETES:  
CAD:  
CVA/TIA:  
H/O SMOKING:                
FAMILY H/O:  
EXAMINATION:  
BLOOD PRESSURE:        ALL PERIPHERAL PULSES:  
CVS:    CVA/TIA:               FUNDUS:  
 
INVESTIGATION:    
ECG:  
BL.SUGAR:        BL.UREA:      SR.CREATININE:  
SR.URIC ACID: 
  
 
   
INFORMATION SHEET 
We are conducting a study on “STUDY ON SERUM URIC 
ACID LEVELS IN ESSENTIAL HYPERTENSION” among patents 
attending Rajiv Gandhi Government General Hospital, Chennai and for 
that your specimen may be valuable to us. 
The purpose of this study is to study the level of uric acid in 
patients with essential hypertension and to study whether  anyassociation 
exists between ages, sex, BMI, smoking, diabetes and target organ 
damage and the elevated uric acid. 
 We are selecting certain cases and f you are eligible, we may be 
using your blood samples to do certain tests which in any way do not 
affect your final report or management. 
 The privacy of the patientsn the research wll be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
 Taking part in the study is voluntary. You are free to decide 
whether to participate in the study or to  withdraw at any time . your 
decision will not result in any loss of benefits to hich you are otherwise 
entitled. 
 The results of this special study may be intimated to you at the end 
of the study perod or during the study if anything is found abnormal 
which may aid in the management or treatment. 
SIGNATURE OF INVESTIGATOR  SIGNATURE OF PARTICIPANT 
SUGANTH.N.G. 
DATE: 
MuhŒ¢á jftš jhŸ 
br‹id uhé›fhªâ muR bghJ kU¤JtkidÆ‹ bghJ 
kU¤Jt¤JiwÆš “ca® ïu¤j mG¤j¤âš Óu« ôÇ¡ mÄy¤â‹ msåL 
F¿¤j MŒî” eilbgW»wJ. 
Ú§fS« ïªj MuhŒ¢áÆš g§nf‰f eh§fŸ ÉU«ò»nwh«. 
ïjdhš j§fsJ á»¢irÆš ghâ¥ò V‰glhJ v‹gijí« 
bjÇÉ¤J¡bfhŸ»nwh«. 
ïªj MŒÉš j§fS¡F kU¤JtgÇnrhjid, ïu¤j¥ gÇnrhjid, 
M»a gÇnrhjidfŸ brŒa¥gL«. 
Koîfis mšyJ fU¤J¡fis btËÆL«nghnjh mšyJ 
MuhŒ¢áÆ‹nghnjh j§fsJ bgaiunah mšyJ milahs§fisnah 
btËÆl kh£nlh« v‹gij bjÇÉ¤J¡bfhŸ»nwh«. 
ïªj MuhŒ¢áÆš g§nf‰gJ j§fSila ÉU¥g¤â‹ngÇšjh‹ 
ïU¡»wJ. nkY« Ú§fŸ vªj neuK« ïªj MuhŒ¢áÆÈUªJ 
ã‹th§fyh« v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«. 
ïªj áw¥ò gÇnrhjidfË‹ Koîfisí« nehÆ‹ j‹ik g‰¿í« 
MuhŒ¢áÆ‹nghJ mšyJ MuhŒ¢áÆ‹ KoÉ‹nghJ j§fS¡F 
m¿É¥ngh« v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«. 
 
 
 MuhŒ¢áahs® ifbah¥g«   g§nf‰ghs® ifbah¥g« 
ehŸ  : 
ïl« : 
PATIENT CONSENT FORM 
Study Detail : “THE  STUDY OF SERUM URIC ACID LEVELS 
IN ESSENTIAL HYPERTENSION” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and 
to immediately inform the study staff if I suffer from any deterioration 
in my health or well being or any unexpected or unusual symptoms. 
Signature/thumb impression                                                                  
 Signature of Investigator 
 
Patient’s Name and Address:                                                                  
Study Investigator’s Name: ❏ 
MuhŒ¢á x¥òjš got« 
MuhŒ¢áÆ‹ jiy¥ò 
ca® ïu¤j mG¤j¤âš Óu« ôÇ¡ mÄy¤â‹ msåL F¿¤j MŒî 
 
MŒî Ãiya« : bghJ kU¤Jt¤Jiw,  
br‹id kU¤Jt¡ fšÿÇ br‹id - 3. 
    
g§F bgWgtÇ‹ bga® :       
cŸnehahË v© : 
g§FbgWgt® ïjid () F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu§fŸ vd¡F 
És¡f¥g£lJ. v‹Dila rªnjf§fis nf£fî«, mj‰fhd jFªj 
És¡f§fis bgwî« thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g§nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹. 
ïªj MŒî r«gªjkhfnth, ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g§FbgW« kU¤Jt® v‹Dila kU¤Jt m¿¡iffis 
gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. eh‹ MŒÉš 
ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid 
Koîfisí« k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® 
nk‰bfhŸS« MŒÉš ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG 
kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g§F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹, ïªj MŒit nk‰bfhŸS« 
kU¤Jt mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹.  
 
 
g§nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
ïlJ if bgUÉuš nuif 
g§nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
MASTER CHART 
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